ARMI will attend BIO 2026 to connect with biotechnology leaders, explore partnership opportunities, and engage in discussions shaping the future of advanced biomanufacturing and regenerative medicine.
ARMI Chief Operating Officer Jennifer MacDonald will participate in a panel discussion at the Cell & Gene Therapy Summit 2026, exploring the scientific, manufacturing, regulatory, and commercialization challenges involved in bringing advanced therapies to patients.
ARMI will attend the Cell & Gene Meeting on the Mesa 2026, one of the industry's leading conferences focused on overcoming the commercialization, manufacturing, and investment challenges facing advanced therapies
ARMI will attend TERMIS-AM 2026, the premier North American conference for tissue engineering and regenerative medicine, bringing together researchers, clinicians, industry leaders, and innovators advancing the future of regenerative therapies.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
